Shield neonatal team in management buyout:
This article was originally published in Clinica
Shield Diagnostics has sold its neonatal test business to its managers for £500,000 ($785,000). The new company is known as Quantase and is backed by a consortium, including a UK bank and venture capital company, 3i. The majority of Quantase's sales come from a test for phenylketonuria.